It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.

Jay Stout Biography and Net Worth

CTO of Immunovant

Jay is the Chief Technology Officer at Immunovant. From 2020 until April 2023, he was an independent consultant supporting the scale up and validation of late-stage products in immunology and cell and gene therapy. From June 2018 until January 2021, he led the Technical Operations at Immunomedics (Gilead) leading to the approval of an antibody drug conjugate for oncology. Prior to that Jay has held various senior leadership roles in Technical Operation at Versartis (Aravive), San Bio, Merck, Amgen, Pfizer, and BioNebraska (Restoragen). He has a proven track record of Biologic approvals for Monoclonal Antibodies, Antibody Drug Conjugates, and Cell and Gene Therapies.

Jay received a B.S. and M.S. in Chemistry from the University of Iowa and a Ph.D. in Chemistry and Biochemistry from the University of Nebraska-Lincoln. Dr. Stout has served on the Amgen Center for BioProcessing Advisory Board at the Keck Graduate Institute for more than 10 years and was the Chair of the Advisory Board from 2021-2023.

What is Jay S. Stout's net worth?: The estimated net worth of Jay S. Stout is at least $3.73 million as of October 23rd, 2024. Mr. Stout owns 142,186 shares of Immunovant stock worth more than $3,726,695 as of November 21st. This net worth approximation does not reflect any other assets that Mr. Stout may own. Learn More about Jay S. Stout's net worth.
How old is Jay S. Stout?: Mr. Stout is currently 60 years old. There are 6 older executives and no younger executives at Immunovant. The oldest executive at Immunovant is Dr. William L. Macias M.D., Ph.D., Chief Medical Officer, who is 65 years old. Learn More on Jay S. Stout's age.
How do I contact Jay S. Stout?: The corporate mailing address for Mr. Stout and other Immunovant executives is 320 WEST 37TH STREET, NEW YORK NY, 10018. Immunovant can also be reached via phone at 917-580-3099 and via email at [email protected]. Learn More on Jay S. Stout's contact information.
Has Jay S. Stout been buying or selling shares of Immunovant?: During the last ninety days, Jay S. Stout has sold $80,912.20 of Immunovant stock. Most recently, Jay S. Stout sold 2,740 shares of the business's stock in a transaction on Wednesday, October 23rd. The shares were sold at an average price of $29.53, for a transaction totalling $80,912.20. Following the completion of the sale, the chief technology officer now directly owns 142,186 shares of the company's stock, valued at $4,198,752.58. Learn More on Jay S. Stout's trading history.
Who are Immunovant's active insiders?: Immunovant's insider roster includes Peter . (), Eva Barnett (CFO), Julia Butchko (Insider), Michael Geffner (Chief Medical Officer), Douglas Hughes (Director), Mark Levine (Chief Legal Officer and Corporate Secretary), William Macias (Insider), George Migausky (Director), Atul Pande (Director), Peter Salzmann (CEO), Jay Stout (CTO), and Frank Torti (Director). Learn More on Immunovant's active insiders.
Are insiders buying or selling shares of Immunovant?: During the last twelve months, insiders at the sold shares 36 times. They sold a total of 204,388 shares worth more than $6,214,884.80. The most recent insider tranaction occured on October, 23rd when insider Mark S Levine sold 4,361 shares worth more than $128,780.33. Insiders at Immunovant own 5.9% of the company. Learn More about insider trades at Immunovant.
Information on this page was last updated on 10/23/2024.

Jay S. Stout Insider Trading History at Immunovant

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/23/2024	Sell	2,740	$29.53	$80,912.20	142,186
7/24/2024	Sell	2,813	$27.76	$78,088.88	144,926
4/24/2024	Sell	7,239	$28.90	$209,207.10	147,739

Jay S. Stout Buying and Selling Activity at Immunovant

Immunovant Company Overview

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Today's Range

Now: $26.21

$25.90

$26.47

50 Day Range

MA: $29.18

$25.22

$31.42

2 Week Range

Now: $26.21

$24.61

$45.58

Volume

126,860 shs

Average Volume

1,078,408 shs

Market Capitalization

$3.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.66

Tesla Execs are Freaking Out

From Angel Publishing | Ad

Click here to get the details.

Jay Stout Biography and Net Worth

What is Jay S. Stout's net worth?

How old is Jay S. Stout?

How do I contact Jay S. Stout?

Has Jay S. Stout been buying or selling shares of Immunovant?

Who are Immunovant's active insiders?

Are insiders buying or selling shares of Immunovant?